CHMP recommends EU-wide Approval of LDK378 for Treatment of adult Patients with ALK- positive NSCLC after Pre Treatment with Crizotinib

Meyer Ina

首页> 外文期刊>Oncology research and treatment. >CHMP recommends EU-wide Approval of LDK378 for Treatment of adult Patients with ALK- positive NSCLC after Pre Treatment with Crizotinib

【24h】

CHMP recommends EU-wide Approval of LDK378 for Treatment of adult Patients with ALK- positive NSCLC after Pre Treatment with Crizotinib

机译：CHMP建议LDK378在欧盟范围内获得批准，以克唑替尼预处理后用于治疗ALK阳性NSCLC的成人患者

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Oncology research and treatment.》 |2015年第5期|共1页
作者
Meyer Ina;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. CHMP recommends EU-wide Approval of LDK378 for Treatment of adult Patients with ALK- positive NSCLC after Pre Treatment with Crizotinib [J] . Meyer Ina Oncology research and treatment. . 2015,第5期

机译：CHMP建议LDK378在欧盟范围内获得批准，以克唑替尼预处理后用于治疗ALK阳性NSCLC的成人患者
2. Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib [J] . Gemma Akihiko, Kusumoto Masahiko, Kurihara Yasuyuki, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2019,第4期

机译：蠕变后肺炎患者肺炎患者的间质肺病发病及其风险因素
3. Treatment status and safety of crizotinib in 2028 Japanese patients with ALK-positive NSCLC in clinical settings [J] . Naomi Ueno, Shigeo Banno, Yutaka Endo, Japanese journal of clinical oncology. . 2019,第7期

机译：临床环境中的2028例日本ALK阳性NSCLC患者的治疗现状和安全性
4. Breast MRI radiomics for the pre-treatment prediction of response to neoadjuvant chemotherapy in node-positive breast cancer patients [C] . Karen Drukker, Iman El-Bawab, Alexandra Edwards, SPIE Conference on Computer-Aided Diagnosis . 2019

机译：乳腺MRI辐射射清，用于节点阳性乳腺癌患者对新辅助化疗的反应预处理预测
5. Pre-Treatment Radiomics Models for Clinical Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC) [D] . Shaffer, Nathan Allen. 2021

机译：早期非小细胞肺癌临床结果的预处理辐射瘤模型（NSCLC）
6. A Patient with Anaplastic Lymphoma Kinase (ALK) FISH Positive NSCLC with Development of Leptomeningeal Carcinomatosis while on Targeted Treatment with Crizotinib [O] . Jonathan W. Riess, Seema Nagpal, Joel W. Neal, -1

机译：接受克唑替尼靶向治疗的间变性淋巴瘤激酶（ALK）FISH阳性NSCLC患者发展为软脑膜癌的患者
7. Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis [O] . Maximilian J. Hochmair, Hannah Fabikan, Oliver Illini, 2020

机译：洛尔替尼在ALK和ROS1重排阳性NSCLC中的后期治疗：回顾性，多中心分析

CHMP recommends EU-wide Approval of LDK378 for Treatment of adult Patients with ALK- positive NSCLC after Pre Treatment with Crizotinib

著录项

相似文献

相关主题

期刊订阅